CUDA Yanqi Lake Meeting | Prof. Nianzeng Xing: Advancing Urology in China Through Multidisciplinary Collaboration

CUDA Yanqi Lake Meeting | Prof. Nianzeng Xing: Advancing Urology in China Through Multidisciplinary Collaboration

2025.04.17
From April 11 to 13, 2025, the 5th Chinese Urological Doctor Association Yanqi Lake Meeting—jointly organized by the Chinese Medical Doctor Association and Chinese Urological Doctor Association—was successfully held in Beijing. The event brought together prominent experts from across the country to explore the future of urology in China. UroStream invited Professor Nianzeng Xing, President of the Chinese Urological Doctor Association and expert from the Cancer Hospital, Chinese Academy of Medical Sciences, to discuss the meeting highlights, the importance of multidisciplinary collaboration, and efforts to improve care in grassroots hospitals.
Blood Science Update|In Vitro Erythropoiesis: The Emerging Potential of Induced Pluripotent Stem Cells (iPSCs)

Blood Science Update|In Vitro Erythropoiesis: The Emerging Potential of Induced Pluripotent Stem Cells (iPSCs)

2025.04.17
Despite over 100 million units of blood being donated annually, supply remains insufficient, particularly for patients with chronic conditions or in crisis settings. Alloimmunization and blood group incompatibilities further constrain transfusion efficacy. In response, researchers are exploring the use of induced pluripotent stem cells (iPSCs) to generate red blood cells (RBCs) in vitro as a reliable and potentially limitless source of transfusable cells. The journal Blood Science (2025) presents a comprehensive review of the current progress, challenges, and future directions of iPSC-derived erythropoiesis.
Blood Science Update|Enhancing Hemophilia A Gene Therapy: Strategic F8 Deletions in AAV8 Vectors

Blood Science Update|Enhancing Hemophilia A Gene Therapy: Strategic F8 Deletions in AAV8 Vectors

2025.04.17
Hemophilia A is a chronic bleeding disorder resulting from a deficiency in coagulation factor VIII (F8). Current treatment strategies rely on frequent F8 replacement therapy, which is limited by its short half-life, high cost, and the risk of inhibitor development. Gene therapy using adeno-associated virus serotype 8 (AAV8) has emerged as a promising modality, offering liver-targeted, long-term transgene expression. This article recently published in Blood Science investigates whether targeted deletions adjacent to the furin cleavage site of F8 can enhance the therapeutic efficacy and safety of AAV8-delivered BDDF8 constructs in a murine model of hemophilia A.
ASCO 2024 | Breakthrough in Combined Therapy with Adebrelimab: Ushering in a New Era for Small Cell Lung Cancer Treatment in China

ASCO 2024 | Breakthrough in Combined Therapy with Adebrelimab: Ushering in a New Era for Small Cell Lung Cancer Treatment in China

2025.04.17
A phase II clinical study on the sequential use of Adebrelimab combined with chemotherapy followed by thoracic radiotherapy has garnered widespread attention at ASCO 2024, particularly for its impact on the treatment of extensive-stage small cell lung cancer (ES-SCLC).The results are striking: the regimen significantly prolonged progression-free survival (PFS) and overall survival (OS) compared to existing standards, while maintaining a favorable safety profile. Most notably, this strategy set a new survival benchmark for first-line immunotherapy in SCLC, demonstrating the value of integrating immune checkpoint inhibition with thoracic radiotherapy. This innovative approach represents a major step forward in SCLC treatment and offers renewed hope for patients battling this aggressive disease. In light of these findings, Oncology Frontier invited Academician Jinming Yu to share insights into the study design, key outcomes, and its clinical implications. The following is a summary of his expert commentary.
CSCO BC | Academician Jinming Yu: Exploring New Directions in Breast Cancer Treatment and Empowering the Next Generation of Oncology Leaders

CSCO BC | Academician Jinming Yu: Exploring New Directions in Breast Cancer Treatment and Empowering the Next Generation of Oncology Leaders

2025.04.17
At the 2025 China National Breast Cancer Conference, CSCO President and Director of Shandong Cancer Hospital, Academician Jinming Yu, delivered a keynote address titled “Precision Integration of Radiotherapy and Immunotherapy in Breast Cancer.” His presentation explored not only the evolving role of radiotherapy in breast cancer treatment but also offered key insights into strengthening China’s scientific innovation capacity in oncology. Following the session, Oncology Frontier invited Academician Yu to share his perspectives on the clinical application of radiotherapy in breast cancer, strategies for advancing China's global competitiveness in oncology, and his long-standing commitment to cultivating young academic talent.